Melanoma: Our Clinical Trials

Clinical trials are research studies that evaluate the safety and effectiveness of new therapies and diagnostic tools, including surgical techniques, chemotherapy drugs, radiation therapy techniques, and vaccines. Clinical trials can also help us compare the effectiveness of prevention strategies or other aspects of your care. If you are eligible to participate in a clinical trial, you may have access to new melanoma therapies that are not yet widely available.

Our treatment team is highly experienced in selecting patients who are most likely to benefit from a particular investigational therapy and can guide you through the process of choosing the most appropriate clinical trial. Learn more about clinical trials.

Here you can find a continually updated listing of Memorial Sloan-Kettering’s current clinical trials for melanoma. To learn more about a study, choose from the list below.

Showing 17 trials
Titlesort icon Investigator
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Melanoma
[Protocol 10-229]
Young, James, MD
A Phase I Study of Ipilimumab in Children, Adolescents, and Young Adults with Treatment-Refractory Cancer
[Protocol 10-193]
Wexler, Leonard, MD
A Phase I/IB Study of IMC-20D7S in Patients with Progressive Malignant Melanoma
[Protocol 10-069]
Wolchok, Jedd, MD, PhD
A Phase I/II Study of CDX-1401 in Patients with Cancers Known to Express NY-ESO-1
[Protocol 09-165]
Keohan, Mary, MD
A Phase I/II Study of Vemurafenib plus Ipilimumab in Patients with V600 BRAF Mutation-Positive Metastatic Melanoma
[Protocol 11-148]
Wolchok, Jedd, MD, PhD
A Phase Ib Study of MDX-1106 (BMS-936558) in Combination with Ipilimumab (BMS-734016) in Patients with Unresectable Stage III or Stage IV Malignant Melanoma
[Protocol 09-155]
Wolchok, Jedd, MD, PhD
A Phase Ib Study of MDX-1106 in Patients with Selected Advanced or Recurrent Malignancies
[Protocol 09-012]
Carvajal, Richard, MD
A Phase IB/II Study of RO4929097 plus Cisplatin, Vinblastine, and Temozolomide in Patients with Metastatic Melanoma
[Protocol 10-085]
Dickson, Mark, MD
A Phase II Study of CT-011 in Patients with Metastatic Melanoma
[Protocol 11-124]
Wolchok, Jedd, MD, PhD
A Phase II Study of Nilotinib (AMN107) in Patients with Metastatic Mucosal, Acral, or Chronically Sun-Damaged Melanoma
[Protocol 09-055]
Carvajal, Richard, MD
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma
[Protocol 10-123]
Carvajal, Richard, MD
A Phase II Study of Vemurafenib in Poor Performance Patients with Inoperable Locally Advanced or Metastatic Melanoma Containing a V600 BRAF Mutation
[Protocol 11-091]
Chapman, Paul, MD
A Phase III Study of Nilotinib (Tasigna?) versus Dacarbazine in Patients with Advanced Melanoma with a c-Kit Mutation (TEAM Trial
[Protocol 10-102]
Carvajal, Richard, MD
A Phase III Study of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy in Patients with Cutaneous Melanomas that Have Metastasized to the Sentinel Node
[Protocol 09-112]
Ariyan, Charlotte, MD
A Study of MORAb-004 Monotherapy in Patients with Metastatic Melanoma
[Protocol 11-088]
D'Angelo, Sandra, MD
Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity
[Protocol 10-101]
Ariyan, Charlotte, MD
Phase II Trial of Temozolomide versus AZD6244 in Patients with Metastatic Uveal Melanoma
[Protocol 10-053]
Carvajal, Richard, MD